Phase I/II Study of S-1 plus Cisplatin Combination Chemotherapy in Patients with Advanced/Recurrent Head and Neck Cancer
Authors:
Open Access
- 23 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 40 (3) , 214-221
Abstract
The objectives of this study were to determine the maximum tolerated dose (MTD) and recommended dose (RD) of S-1 plus cisplatin (CDDP) and to evaluate safety and efficacy using the defined RD in advanced/recurrent head and neck cancer (HNC). S-1 was administered orally at 40 mg/m2 twice daily for 14 consecutive days, and CDDP was infused on day 8 at a dose of 60 and 70 mg/m2. Each course was repeated every 4 weeks. A total of 38 patients were registered, 10 patients for the Phase I study and an additional 28 patients for the Phase II study. Although no dose-limiting toxicity (DLT) was observed in the CDDP 60 mg/m2 (Level 1) group, two of six patients in the CDDP 70 mg/m2 (Level 2) group exhibited DLT (fatigue/diarrhea). The MTD was not achieved in the Phase I study. Level 2 was therefore determined as the RD. In the Phase II study, 34 patients, including 6 patients from the Phase I study, were evaluated. At the termination of treatment, the confirmed response rate was 44.1% (15/34, 95% CI: 27.4–60.8). The best response rate without an adequate duration time was 67.6% (95% CI: 51.9–83.4). The median survival period was 16.7 months, and the 1-year survival rate was 60.1%. The main toxicities of Grade 3 or above were anorexia (26.5%), nausea (14.7%), neutropenia/thrombocytopenia (11.8%) and anemia/fatigue (8.8%). This is considered to be an effective regimen with acceptable toxicities for HNC.Keywords
This publication has 20 references indexed in Scilit:
- A late phase II study of S-1 for metastatic pancreatic cancerCancer Chemotherapy and Pharmacology, 2007
- An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic CancerOncology, 2005
- S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2004
- A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working groupBreast Cancer, 2004
- Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerBritish Journal of Cancer, 2003
- Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinomaBritish Journal of Cancer, 2000
- Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric CancerOncology, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- Head and Neck CancerNew England Journal of Medicine, 1993
- Overview of Combined Modality Therapies for Head and Neck CancerJNCI: Journal of the National Cancer Institute, 1993